Evidence map›Paper›PMID 38217297›Full record

ArticleCytometry. Part B, Clinical cytometry2024

Standardization of flow cytometric detection of antigen expression.

Linhua Tian, Aaron R Nelson, Tyler Lowe, Linda Weaver, Constance Yuan, Hao-Wei Wang, Paul DeRose, Maryalice Stetler-Stevenson, Lili Wang

Abstract read
In one paragraph

Article in Cytometry. Part B, Clinical cytometry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Linhua TianBiosystems and Biomaterials Division, National Institute of Standards and Technology (NIST), Gaithersburg, Maryland, USA.
Aaron R NelsonLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Tyler LoweLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Linda WeaverLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Constance YuanLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0002-2601-3665
Hao-Wei WangLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0002-5408-9253
Paul DeRoseBiosystems and Biomaterials Division, National Institute of Standards and Technology (NIST), Gaithersburg, Maryland, USA.
Maryalice Stetler-StevensonLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Lili WangBiosystems and Biomaterials Division, National Institute of Standards and Technology (NIST), Gaithersburg, Maryland, USA.

Funding

Flow Cytometric Evaluation of BiomarkersZICBC011104 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WANG, HAO-WEI · 2009 to 2025
$8.6M
Intramural NIST DOC 9999-NIST
6 · The paper itself

Abstract

Since response to antigen-based immunotherapy relies upon the level of tumor antigen expression we developed an antigen quantification assay using ABC values. Antigen quantification as a clinical assay requires methods for quality control and for interlaboratory and inter-cytometer platform standardization. A single lot of Cytotrol™ Lyophilized Control Cells (Beckman Coulter) used for all studies. The variability in antigen quantification across 4 different instrument platforms in 2 separate laboratories was evaluated. The effect of the antibody clone utilized, importance of custom 1:1 molar ratio (fluorophore to protein, F/P) verses off-the-shelf antibodies, and QuantiBrite PE calibration verses linearity calibration combined with a single point scale transformation with CD4 as reference were determined. Use of single lot control cells allowed validation of reproducibility between flow cytometer platforms and laboratories and allowed assessment of different antibody lots, cocktail preparation, and different antibody clones. Off the shelf antibody preparations provide reproducible estimates of antigen density, however custom 1:1 unimolar antibody preparations should be utilized for definitive measurement of antigen expression.Geometric Mean fluorescent Intensity (GeoMFI) was not comparable across instruments and inter-laboratory. The use of CD4 as the reference marker can minimize variability in ABC values. Comparable antigen quantification is vital in managing patients receiving antigen-based immunotherapy. If this assay is to be utilized in a clinical setting, quality control methods have to be instituted to assure reproducibility and allow validation across laboratories. We have demonstrated that use of a lyophilized cell control is highly valuable in achieveing these goals.

Indexed as

AntibodiesAntigensFlow CytometryHumansReference StandardsReproducibility of ResultsAntibodiesAntigensacute leukemiaFlow cytometryLeukemiaQunatificationStandardization

Identifiers

PMID38217297
PMCPMC10922571

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.